EUVIMEDSkopri EUVIMED
Crossref

Dynamic path analysis for exploring treatment effect mediation processes in clinical trials with time‐to‐event endpoints

Matthias Kormaksson, Markus Reiner Lange, David Demanse, Susanne Strohmaier, Jiawei Duan, Qing Xie, Mariana Carbini, Claudia Bossen, Achim Guettner, Antonella Maniero

Statistics in Medicine · 2024

DOI: 10.1002/sim.10191 ↗

At a glance

Journal article in Statistics in Medicine, 2024. Written by Matthias Kormaksson and 9 co-authors. Institution: Analytics, Development, Novartis Pharma AG, Basel, Switzerland. Major MEDLINE topics: Mediation Analysis. Cited 3 times so far (Crossref); 34 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Why does a beneficial treatment effect on a longitudinal biomarker not translate into overall treatment benefit on survival, when the biomarker is in fact a prognostic factor of survival? In a recent exploratory data analysis in oncology, we were faced with this seemingly paradoxical result. To address this problem, we applied a theoretically principled methodology called dynamic path analysis, which allows us to perform mediation analysis with a longitudinal mediator and survival outcome. The aim of the analysis is to decompose the total treatment effect into a direct treatment effect and an indirect treatment effect mediated through a carefully constructed mediation path. The dynamic nature of the underlying methodology enables us to describe how these effects evolve over time, which can add to the mechanistic understanding of the underlying processes. In this paper, we present a detailed description of the dynamic path analysis framework and illustrate its application to survival mediation analysis using simulated and real data. The use case analysis provides clarity on the specific exploratory question of interest while the methodology generalizes to a wide range of applications in drug development where time‐to‐event is the primary clinical outcome of interest.

Subjects

MeSH terms (MEDLINE)

Mediation AnalysisHumansSurvival AnalysisComputer SimulationTreatment OutcomeModels, StatisticalClinical Trials as TopicEndpoint DeterminationBiomarkers

Author keywords

direct effectsdynamic path analysisindirect effectstotal effects

Substances

Biomarkers

Authors and institutions

  • Analytics, Development, Novartis Pharma AG, Basel, Switzerland.
  • Department of Epidemiology, Medical University of Vienna, Vienna, Austria.
  • Analytics, Development, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.

Cite

APA

Kormaksson, M., Lange, M. R., Demanse, D., Strohmaier, S., Duan, J., Xie, Q., Carbini, M., Bossen, C., Guettner, A., & Maniero, A. (2024). Dynamic path analysis for exploring treatment effect mediation processes in clinical trials with time‐to‐event endpoints. Statistics in Medicine. https://doi.org/10.1002/sim.10191

Vancouver

Kormaksson M, Lange MR, Demanse D, Strohmaier S, Duan J, Xie Q, et al. Dynamic path analysis for exploring treatment effect mediation processes in clinical trials with time‐to‐event endpoints. Statistics in Medicine. 2024. doi:10.1002/sim.10191

BibTeX
@article{Kormaksson2024,
  author = {Kormaksson, Matthias and Lange, Markus Reiner and Demanse, David and Strohmaier, Susanne and Duan, Jiawei and Xie, Qing and Carbini, Mariana and Bossen, Claudia and Guettner, Achim and Maniero, Antonella},
  title = {Dynamic path analysis for exploring treatment effect mediation processes in clinical trials with time‐to‐event endpoints},
  journal = {Statistics in Medicine},
  year = {2024},
  doi = {10.1002/sim.10191}
}
Start for free →